Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can an oxygen gel heal medication-damaged jaw bone better than a blood-derived patch?

NCT ID NCT07725107

Disease control Sponsor: Mansoura University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial compares two treatments applied during surgery to help heal jaw bone damage caused by bisphosphonates or similar drugs. One is an oxygen-based gel, the other is a membrane made from the patient's own platelets. Researchers will measure how completely the bone and soft tissue heal, and whether patients have less pain afterward.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an oxygen-based gel (Blue®m) or platelet-rich fibrin (PRF) membrane applied during surgery
What this could lead to
If one of these approaches works better, it could offer a simpler, more effective way to heal jaw bone damage caused by certain medications.
What could go wrong
This is a small, early-stage trial with only 36 participants, so results may not apply to everyone. Both treatments are applied during surgery, and healing may still fail.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

36 people

The number who actually took part.

Started

Apr 2026

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient Age: ≥18 years. * Patients diagnosed with BRONJ/MRONJ Stage 1-3 (AAOMS criteria).(25) * History of antiresorptive or antiangiogenic drug use. * Patients willing to participate in the study's follow-up intervals and to provide informed consent. Exclusion Criteria: * Previous radiotherapy to head and neck * Uncontrolled systemic disease (e.g., uncontrolled diabetes) * Pregnancy or lactation * Known allergy to Blue®m components * Uncooperative patients.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bisphosphonate related osteonecrosis of the jaws (bronj) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bisphosphonate-Associated Osteonecrosis of the Jaw injury osteonecrosis of the jaw

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bisphosphonate related osteonecrosis of the jaws (bronj) OXYGEN Topical administration Wound healing

Contacts and locations

Locations

  • Faculty of Dentistry Mansoura University

    Al Mansurah, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.